Clinical trials
Phase 1 Carcinoma, Transitional Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
142 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 15 |
| 2019 | 15 |
| 2020 | 16 |
| 2021 | 13 |
| 2022 | 7 |
| 2023 | 9 |
| 2024 | 10 |
| 2025 | 10 |
| 2026 | 15 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 54 |
| Terminated | 28 |
| Recruiting | 25 |
| Active, not recruiting | 22 |
| Unknown status | 4 |
| Not yet recruiting | 3 |
| Suspended | 2 |
| Enrolling by invitation | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 6 |
| Pfizer | 5 |
| H. Lee Moffitt Cancer Center and Research Institute | 4 |
| Xencor, Inc. | 4 |
| Exelixis | 3 |
| Incyte Corporation | 3 |
| Jonsson Comprehensive Cancer Center | 3 |
| M.D. Anderson Cancer Center | 3 |
| Affiliated Hospital of Jiangnan University | 2 |
| Bristol-Myers Squibb | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 142 |
| Carcinoma, Non-Small-Cell Lung | 62 |
| Melanoma | 42 |
| Carcinoma, Renal Cell | 41 |
| Squamous Cell Carcinoma of Head and Neck | 40 |
| Urinary Bladder Neoplasms | 37 |
| Colorectal Neoplasms | 31 |
| Stomach Neoplasms | 30 |
| Ovarian Neoplasms | 28 |
| Triple Negative Breast Neoplasms | 26 |
Trials
Showing 76 to 100 of 142. Each trial links to its page on Pharma Observatory.
42 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.